OGT SureSeq Myeloid Fusion Panel

Tuesday, 07 May, 2024 | Supplied by: Sysmex Australia Pty Ltd

OGT, a Sysmex Group company, has launched the RNA-based SureSeq Myeloid Fusion Panel — a next-generation sequencing (NGS) tool for identifying key fusion genes implicated in acute myeloid leukaemia (AML).

Intelligently designed in collaboration with myeloid cancer experts, the panel can efficiently identify over 30 key disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay. By utilising a partner-gene agnostic approach, fusions with multiple partners as well as novel and rare fusions can be identified, expanding the ability to classify samples.

The panel is fully compatible with OGT’s existing end-to-end Universal NGS Complete Workflow Solution and data analysis software, Interpret, to minimise hands-on time and provide easy analysis without the need for additional bioinformatics resources. It is a valuable tool for myeloid research that is supported by an efficient workflow, enabling users to rapidly detect the most relevant fusion genes in a single assay.

Online: www.sysmex.com.au
Phone: 02 9016 3040
Related Products

Revvity Horizon Discovery Pin-point Base Editing Platform

The Horizon Discovery Pin-point Base Editing platform from Revvity, with its novel three-part...

ACROBiosystems target antigens for CAR-T therapy development

ACROBiosystems' growing list of proteins includes many fluorescent-labelled target antigens...

Sophion Bioscience QPatch II automated patch clamp system

QPatch, by Sophion Bioscience, is an automated patch clamp solution for cardiac safety and...

  • All content Copyright © 2024 Westwick-Farrow Pty Ltd